Maintenance treatment with the immunomodulator MGN1703, a Toll-like receptor 9 (TLR9) agonist, in patients with metastatic colorectal carcinoma and disease control after chemotherapy: a randomised, double-blind, placebo-controlled trial

PURPOSE: This phase II study evaluated the synthetic DNA-based immunomodulator and Toll-like receptor 9 agonist MGN1703 as maintenance treatment in metastatic colorectal carcinoma (mCRC). METHODS: Fifty-nine patients with mCRC and disease control after standard first-line chemotherapy were randomise...

Descripción completa

Detalles Bibliográficos
Autores principales: Schmoll, Hans-Joachim, Wittig, Burghardt, Arnold, Dirk, Riera-Knorrenschild, Jorge, Nitsche, Dieter, Kroening, Hendrik, Mayer, Frank, Andel, Johannes, Ziebermayr, Reinhard, Scheithauer, Werner
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2014
Materias:
Original Article – Clinical Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4131138/
https://www.ncbi.nlm.nih.gov/pubmed/24816725
http://dx.doi.org/10.1007/s00432-014-1682-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4131138/
https://www.ncbi.nlm.nih.gov/pubmed/24816725
http://dx.doi.org/10.1007/s00432-014-1682-7

Ejemplares similares